Related Experiment Videos
Transmyocardial CO(2) laser revascularization improves symptoms, function, and quality of life: 12-month results from
J A Spertus1, P G Jones, M Coen
1Section of Cardiology, Mid America Heart Institute/University of Missouri--Kansas City 64111, USA.
Insights
Transmyocardial revascularization significantly improved angina, physical function, and quality of life in patients with severe coronary artery disease compared to medical management. These benefits were sustained for one year, offering a valuable palliative option.
Area of Science:
- Cardiology
- Surgical Innovation
- Patient Outcomes
Background:
- Severe, symptomatic, inoperable coronary artery disease presents significant challenges for patient health status.
- Current medical management may not adequately address symptoms, physical function, and quality of life in these patients.
Purpose of the Study:
- To compare health status outcomes between transmyocardial revascularization (TMR) using a carbon dioxide laser and continued medical management.
- To evaluate symptom relief, physical function, and quality of life in patients with severe coronary artery disease.
Main Methods:
- A prospective, multicenter trial randomized 197 patients to either TMR or continued medical therapy.
- Health status was assessed using the Seattle Angina Questionnaire and Short Form-36 at baseline and 3, 6, and 12 months.
- A novel 'benefit statistic' was employed for enhanced interpretability of disease-specific health status.
Main Results:
- Patients randomized to TMR experienced a 44% reduction in angina, compared to 21% in the medical group (p<0.001).
- Significant improvements were observed in physical limitations (23% difference) and quality of life (26% difference) for the TMR group.
- Benefits were evident by 3 months and maintained throughout the 1-year follow-up period.
Conclusions:
- Transmyocardial revascularization serves as a potentially valuable palliative treatment for patients with severe, inoperable coronary artery disease.
- TMR offers significant improvements in health status for patients with limited revascularization options.
Purpose:
To describe differences in health status (symptoms, physical function, and quality of life) between continued medical management and transmyocardial revascularization with a carbon dioxide laser in patients with severe, symptomatic, inoperable coronary artery disease.
Subjects And Methods:
This prospective, multicenter trial randomized 98 patients to transmyocardial revascularization and 99 to continued medical therapy. Health status was assessed with the Seattle Angina Questionnaire and the Short Form-36 at baseline and at 3, 6, and 12 months. A new analytic technique, the benefit statistic, was developed to facilitate interpretability of disease-specific health status assessments over time.
Results:
Of the 99 patients assigned to medical therapy, 59 (60%) subsequently underwent transmyocardial revascularization. By an intention-to-treat analysis, patients initially randomized to transmyocardial revascularization had 44% of their angina eliminated versus 21% for the medical treatment group (difference = 23%; 95% confidence interval [CI], 11% to 34%). Differences in the benefits of transmyocardial revascularization on physical limitations (33% vs 11% in the medical arm [difference = 23%; 95% CI, 15% to 31%]) and quality of life (47% vs 20% in the medical arm [difference = 26%; 95% CI, 18% to 35%]) were similarly large. These benefits were apparent at 3 months and sustained throughout the 1 year of follow-up. An efficacy analysis that excluded patients who crossed over from the medical treatment to transmyocardial revascularization arm suggested greater treatment benefits.
Conclusions:
Transmyocardial revascularization may offer a valuable palliative alternative to patients with severe limitations in health status for whom no standard revascularization options exist.